GLP-1 RA — Pharmacokinetics Comparison
Side-by-side comparison of 5 GLP-1 RA drugs with interactive PK simulators. Compare dosing, routes of administration, indications, and pharmacokinetic profiles.
| Drug | Route | Model Type | Indication | Therapeutic Area | Simulator |
|---|---|---|---|---|---|
| Ozempic (Semaglutide) | SC | 1-CMT PopPK | Type 2 diabetes mellitus | Endocrinology | Open → |
| Rybelsus (Oral Semaglutide) | Oral | 1-CMT PopPK | Type 2 diabetes mellitus | Endocrinology | Open → |
| Semaglutide | SC | PK/PD | Type 2 Diabetes / Obesity | Metabolic | Open → |
| Trulicity (Dulaglutide) | SC | 1-CMT PopPK | Type 2 diabetes mellitus | Endocrinology | Open → |
| Wegovy (Semaglutide) | SC | 1-CMT PopPK | Chronic weight management | Endocrinology | Open → |
Individual Drug Profiles
Ozempic (Semaglutide)
- Route
- SC
- Model Type
- 1-CMT PopPK
- Indication
- Type 2 diabetes mellitus
- Therapeutic Area
- Endocrinology
Rybelsus (Oral Semaglutide)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Type 2 diabetes mellitus
- Therapeutic Area
- Endocrinology
Semaglutide
- Route
- SC
- Model Type
- PK/PD
- Indication
- Type 2 Diabetes / Obesity
- Therapeutic Area
- Metabolic
Trulicity (Dulaglutide)
- Route
- SC
- Model Type
- 1-CMT PopPK
- Indication
- Type 2 diabetes mellitus
- Therapeutic Area
- Endocrinology
Wegovy (Semaglutide)
- Route
- SC
- Model Type
- 1-CMT PopPK
- Indication
- Chronic weight management
- Therapeutic Area
- Endocrinology
Key Differences
Routes of Administration
SCOral
Therapeutic Areas
EndocrinologyMetabolic
Indications
- • Type 2 diabetes mellitus
- • Type 2 Diabetes / Obesity
- • Chronic weight management
Disclaimer: This comparison is for educational and research purposes only. Pharmacokinetic parameters are derived from published population PK models and may not reflect individual patient variability. Drug selection and dosing should always be guided by clinical judgment, prescribing information, and applicable guidelines. Not intended for clinical use.